Setbacks for Endostatin

See allHide authors and affiliations

Science  22 Mar 2002:
Vol. 295, Issue 5563, pp. 2198-2199
DOI: 10.1126/science.295.5563.2198

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Harvard University's Judah Folkman electrified cancer researchers 5 years ago when he and his colleagues reported on a new compound that could shrink tumors in mice virtually to nothing by cutting off the blood supply to tumors, rather than by poisoning patients with toxic drugs. Now, as clinical trials of the widely heralded cancer treatment endostatin are about to be expanded, two groups report that they couldn't get it to work. Although these papers are not the first to raise questions about endostatin, they are among the most pointed.